Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant humanized anti-IL-6R mAb in moderate-to-severe active rheumatoid arthritis
CTR20220613Phase 2Completed
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VDJ-001 in rheumatoid arthritis (RA), sponsored by Beijing VDJBio Co., Ltd.. Started Mar 2022; status: completed.
02
Drugs
VDJ-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20220613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220613.